Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2022 07:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration...
February 24, 2022 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA...
January 11, 2021 07:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Provides Corporate Update and 2021 Outlook

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
November 30, 2020 16:05 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating...